Mission Pharmacal Submits Supplemental New Drug Application For Tindamax(R) (Tinidazole) As Treatment Of Bacterial Vaginosis

... Mission Pharmacal todayannounced that the company has submitted a supplemental new drugapplication (sNDA) with the U.S. Food and Drug Administration (FDA) for anew indication for Tindamax® (tinidazole) as treatment of bacterialvaginosis (BV), the most common vaginal infection in the United States. [click link for full article] ...